Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-22

FDA Approved: CARDURA XL — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

FDA has approved a supplemental application for CARDURA XL (doxazosin mesylate) submitted by Viatris Specialty LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CARDURA XL (DOXAZOSIN MESYLATE)

Snippet

SUPPL AP for CARDURA XL (DOXAZOSIN MESYLATE)